Parathyroid Hormone Market Research Reveals Strong 11.9% CAGR Outlook Through 2030

Understanding the growth trajectory of the parathyroid hormone market reveals promising advancements and expanding opportunities. This sector is witnessing significant development driven by medical innovation and increasing healthcare infrastructure worldwide. Let's explore the current market size, key drivers, major participants, emerging trends, and detailed segmentation to get a comprehensive picture of the parathyroid hormone industry's future.

Parathyroid Hormone Market Size Expansion Until 2030
The market for parathyroid hormone has experienced considerable growth in recent years. It is projected to increase from $2.51 billion in 2025 to $2.8 billion in 2026, reflecting a compound annual growth rate (CAGR) of 11.5%. The rise over the past years is largely due to factors such as the scarce availability of recombinant parathyroid hormone, low patient awareness about the underlying diseases, dependence on traditional vitamin D therapy, and the expansion of hospital and clinical facilities. Additionally, the growing incidence of complications after parathyroid surgeries has contributed to this growth.

Download a free sample of the parathyroid hormone market report:
https://thebusinessresearchcompany.com/sample_request?id=91084685&type=smp&name=Parathyroid%20Hormone%20Market%20Report%202026&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

Forecast for Future Growth and Influencing Factors in the Parathyroid Hormone Market
Looking ahead, this market is expected to grow rapidly, reaching a value of $4.4 billion by 2030 with a CAGR of 11.9%. This anticipated expansion is driven by advancements in parathyroid hormone analogues, increased adoption of personalized medicine, broader hospital and specialty clinic networks, and the integration of digital tools for patient monitoring. Moreover, heightened government and healthcare initiatives targeting hypocalcemia and hypoparathyroidism are providing further momentum. Key trends shaping the market include a rising prevalence of hypocalcemia and hypoparathyroidism, expanding use of recombinant parathyroid hormone therapies, and the growth of tailored treatment options through parathyroid hormone analogues. Post-surgical management and vitamin D supplementation remain essential components of patient care, supporting market growth.

Key Players Defining the Parathyroid Hormone Market Landscape
The parathyroid hormone market includes several prominent companies, such as Pfizer Inc., Eli Lilly and Company, Radius Health Inc., Ascendis Pharma, Entera Bio Ltd., Extend Biosciences Inc., Gedeon Richter Plc., Abbott Laboratories, Amgen Inc., Merck & Co. Inc., Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., Alcon Laboratories Inc., Bayer Healthcare, AstraZeneca PLC, Biocon, Dr. Reddy's Laboratories, Glenmark Pharmaceuticals, Jubilant Life Sciences, Lupin Limited, Sun Pharmaceutical Industries, Torrent Pharmaceuticals, Wockhardt, and Cipla Limited.

View the full parathyroid hormone market report:
https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

Strategic Partnerships Shaping Market Innovation
In November 2023, Ascendis Pharma A/S, a biopharmaceutical company based in Denmark, announced a partnership with Japan's Teijin Limited to promote the development and commercialization of new therapies. This collaboration focuses on improving access to Ascendis Pharma's pipeline products, advancing patient care in Japan, and fostering innovation within the rare disease and endocrine treatment sectors. Teijin Limited specializes in healthcare and pharmaceutical solutions aimed at addressing unmet medical needs.

Emerging Trends Highlighting Opportunities in the Parathyroid Hormone Sector
Leading firms in this market are concentrating on creating biosimilars of parathyroid-based drugs, including prodrugs of parathyroid hormone (PTH), to broaden treatment options. Prodrugs are inactive compounds that convert into active hormones post-administration, allowing for sustained release and stable therapeutic effects related to calcium regulation and bone health. For example, in August 2024, Ascendis Pharma A/S received FDA approval for YORVIPATH (palopegteriparatide), the first and only treatment specifically for adult hypoparathyroidism. This once-daily prodrug ensures continuous PTH exposure, potentially benefiting between 70,000 and 90,000 patients in the U.S. Ascendis Pharma supports patients through its ascendis signature access program (A.S.A.P.); however, users must periodically monitor serum calcium to avoid hypercalcemia or hypocalcemia.

Detailed Segmentation of the Parathyroid Hormone Market
This report categorizes the parathyroid hormone market into several segments:
1) By Disease Type: Hypocalcemia, Hypoparathyroidism
2) By Product Type: Recombinant Parathyroid Hormone, Parathyroid Hormone Analogues
3) By End-User: Hospitals, Clinics, Other End-Users

Further breakdown includes:
- Hypocalcemia subtypes such as Pseudohypoparathyroidism and Vitamin D Deficiency
- Hypoparathyroidism subtypes including Post-Surgical Hypoparathyroidism and Idiopathic Hypoparathyroidism

This structured segmentation provides precise insight into the market's diverse therapeutic areas and product classifications, aiding stakeholders in understanding demand drivers and growth avenues.

What's included in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.